来曲唑与他莫昔芬单药或序贯辅助治疗绝经后激素受体阳性乳腺癌:BIG 1-98 试验长期随访
BIG 1-98 是一项四臂、III 期、双盲、随机试验,比较绝经后内分泌反应性早期乳腺癌患者辅助来曲唑与他莫昔芬单药(各 5 年)及序贯方案的疗效与不良事件。中位随访 12.6 年的长期随访结果显示,来曲唑单药对比他莫昔芬的无病生存事件风险相对降低 9%(HR 0.91;95%CI 0.81-1.01),对侧乳腺癌疗效随时间显著变化(0-5 年、5-10 年、>10 年 HR 分别为 0.62、0.47、1.35;治疗-时间交互 P=0.005)。
要点
- 来曲唑对比他莫昔芬单药的无病生存事件风险相对降低 9%(HR 0.91;95%CI 0.81-1.01)。
- 对侧乳腺癌疗效随时间显著变化(0-5 年、5-10 年、>10 年 HR 分别为 0.62、0.47、1.35;交互 P=0.005)。
- 来曲唑降低前 10 年对侧乳腺癌频率,但 10 年后该效应反转。
核心结论
- 疗效终点持续显示有利于来曲唑的趋势。
- 来曲唑降低前 10 年对侧乳腺癌频率,但 10 年后该效应反转。
- 本研究说明在管腔型乳腺癌试验中进行延长随访的价值。
研究设计与样本
- BIG 1-98 是一项四臂、III 期、双盲、随机试验,比较辅助来曲唑与他莫昔芬单药(各治疗 5 年)及序贯方案(一种治疗 2 年加另一种 3 年),纳入绝经后内分泌反应性早期乳腺癌女性。
- 当制药公司资助在中位随访 8.4 年结束时终止后,学术合作方启动观察性长期随访扩展,每年收集生存、疾病状态和不良事件数据。
- 丹麦信息来自丹麦乳腺癌协作组登记库,报告意向治疗分析。
- 共入组 8,010 例患者,其中 4,433 例在参与长期随访的中心存活且未退出,3,833 例(86%)至少有 1 份长期随访报告。
主要发现
- 来曲唑对比他莫昔芬单药的无病生存事件风险相对降低 9%(HR 0.91;95%CI 0.81-1.01)。
- 其他疗效终点的 HR 与无病生存相似。
- 来曲唑对比他莫昔芬对侧乳腺癌的疗效随时间显著变化(0-5 年、5-10 年、>10 年 HR 分别为 0.62、0.47、1.35;治疗-时间交互 P=0.005),可能反映他莫昔芬更长的后续效应。
- 特定长期不良事件的报告使用国家登记库似乎比临床随访病历报告更有效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after diagnosis. We analyzed long-term follow-up (LTFU) of efficacy outcomes and adverse events in the Breast International Group (BIG) 1-98 study reported after a median follow-up of 12.6 years. PATIENTS AND METHODS: BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) and their sequences (2 years of one treatment plus 3 years of the other) for postmenopausal women with endocrine-responsive early breast cancer. When pharmaceutical company sponsorship ended at 8.4 years of median follow-up, academic partners initiated an observational, LTFU extension collecting annual data on survival, disease status, and adverse events. Information from Denmark was from the Danish Breast Cancer Cooperative Group Registry. Intention-to-treat analyses are reported. RESULTS: Of 8,010 enrolled patients, 4,433 were alive and not withdrawn at an LTFU participating center, and 3,833 (86%) had at least one LTFU report. For the monotherapy comparison of letrozole versus tamoxifen, we found a 9% relative reduction in the hazard of a disease-free survival event with letrozole (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.01). HRs for other efficacy end points were similar to those for disease-free survival. Efficacy of letrozole versus tamoxifen for contralateral breast cancer varied significantly over time (0- to 5-, 5- to 10-, and > 10-year HRs, 0.62, 0.47, and 1.35, respectively; treatment-by-time interaction P = .005), perhaps reflecting a longer carryover effect of tamoxifen. Reporting of specific long-term adverse events seemed more effective with national registry than with case-record reporting of clinical follow-up. CONCLUSION: Efficacy end points continued to show trends favoring letrozole. Letrozole reduced contralateral breast cancer frequency in the first 10 years, but this reversed beyond 10 years. This study illustrates the value of extended follow-up in trials of luminal breast cancer.
引用
- Ruhstaller T, Giobbie-Hurder A, Colleoni M, et al. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol. 2018. PMID: 30475668. doi:10.1200/JCO.18.00440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。